PET scans to track immune response in lung cancer treatment
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study uses special PET scans to see how well your immune cells respond to immunotherapy given before surgery for non-small cell lung cancer. The goal is to learn which patients benefit most from this treatment approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that can be seen on a PET scan with a tumor at least 2 cm (about the size of a grape) in the lung or nearby lymph nodes
- You are scheduled to have chemotherapy and immunotherapy before surgery to remove the tumor
- You are generally healthy and able to take care of yourself (ECOG score of 0 or 1) and your lungs are strong enough for surgery
- You have not had your spleen removed, and you have not received any vaccine or high-dose steroids in the 2 weeks before the trial starts
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan can predict how well your tumor responds to an immunotherapy drug given before surgery. Participation may help doctors tailor your treatment and improve outcomes for early-stage lung cancer.
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
This trial uses a special PET scan to see how immune cells (CD8 T cells) are working in your tumor before you start a PD-1 immunotherapy drug (nivolumab or cetrelimab). The goal is to find out if the scan can predict whether the immunotherapy will work for you.
This study tests if a new type of PET scan can see changes in your immune system when you receive immunotherapy for non-small cell lung cancer. It may help doctors understand how well your treatment is working.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.